Cadrenal Therapeutics, Inc. (CVKD) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for cardiovascular conditions. Its lead product candidate is tecarfarin, a reversible Vitamin K antagonist for patients with end-stage kidney disease and atrial fibrillation (ESKD+AFib) and those with left ventricular assist devices (LVADs). The company also recently acquired assets from eXIthera Pharmaceuticals, including frunexian, an IV Factor XIa inhibitor for acute care settings. This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | Balance Sheet (Sep 30, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2.69) million | $(10.20) million | N/A |
| Operating Expenses | $(2.73) million | $(10.40) million | N/A |
| Cash & Equivalents | N/A | N/A | $3.86 million |
| Working Capital | N/A | N/A | $2.73 million |
| Accumulated Deficit | N/A | N/A | $(35.92) million |
| Cash Used in Operations (YTD) | N/A | $(10.03) million | N/A |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased 11% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 56% year-over-year (YTD 2025 vs. YTD 2024).
- General & Administrative (G&A): Increased 22% in Q3 and 73% YTD, driven by public company costs, stock-based compensation, and consulting fees.
- Research & Development (R&D): Decreased 12% in Q3 but increased 29% YTD. The YTD increase included transaction costs related to the eXIthera asset acquisition and severance costs.
- Liquidity: Cash and cash equivalents decreased from $10.02 million at year-end 2024 to $3.86 million at September 30, 2025, a reduction of approximately $6.16 million.
- Financing: The company raised approximately $4.02 million in gross proceeds through its At-The-Market (ATM) facility during the first nine months of 2025.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. Current cash resources are insufficient to fund operations for the next 12 months. The company intends to raise additional funds through equity offerings, debt financing, or partnerships, but there is no assurance such funding will be available.
- Strategic Acquisition: On September 12, 2025, the company acquired assets from eXIthera Pharmaceuticals for an initial payment of $50,000 plus transaction costs, with potential milestone payments up to $15 million and royalties. The assets were expensed as in-process R&D.
- Regulatory Risks: The filing highlights risks associated with a potential U.S. federal government shutdown, which could delay FDA reviews, clinical trial approvals, and access to capital markets.
- Capital Needs: The company anticipates increased R&D expenses as it commences clinical trials for tecarfarin and the newly acquired assets.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.86 million cash balance against the projected burn rate of ~$10 million per nine months.
- Financing Plans: Confirm the status of any pending equity offerings or partnership discussions to address the going concern uncertainty.
- Acquisition Milestones: Review the specific clinical milestones required to trigger the $15 million in contingent payments to eXIthera.
- Government Shutdown Impact: Assess the potential delay to FDA interactions and clinical trial timelines due to federal funding issues.
- Dilution Risk: Monitor the volume of shares sold via the ATM facility and the impact of outstanding warrants (615,940 shares) and options (426,333 shares) on future dilution.